Aquinox Pharmaceuticals Inc., of Vancouver, British Columbia, said it presented additional exploratory analyses of responder rates for average daily pain and maximum daily pain from its LEADERSHIP phase II trial in patients with bladder pain syndrome/interstitial cystitis (BPS/IC) at the International Society for the Study of BPS (ESSIC) conference in Rome.